Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:APRI

Apricus Biosciences (APRI) Stock Price, News & Analysis

Apricus Biosciences logo

About Apricus Biosciences Stock (NASDAQ:APRI)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
2 shs
Average Volume
558,386 shs
Market Capitalization
$14,000.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system disorders. The firm's portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior in Major Depressive Disorder �or Post-Traumatic Stress Disorder, �amyotrophic lateral sclerosis, Sanfilippo syndrome, Parkinson's disease, other psychiatric and movement disorders plus orphan diseases. The company was founded by Raj Mehra in 2016 and is headquartered in New York, NY.

Receive APRI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Apricus Biosciences and its competitors with MarketBeat's FREE daily newsletter.

APRI Stock News Headlines

Only a handful of people know the setup that's defied these chaotic markets.
Since February, we've hit 28 out of 29 trades – that's a 96% win rate taking simple options setups on one single ticker every day. That's why Jack Carter and I teamed up to reveal The 4PM Payout Plan. Our goal here was to show you how to take these daily setups every morning to collect a 4PM payout. Naturally, no one can guarantee what the market does in the future… But these simple daily options setups have paid out with the market rallying, dropping, or staying flat. And if you want to be one of the few to not just know the ropes behind these daily setups but also deploy them for yourself…
See More Headlines

APRI Stock Analysis - Frequently Asked Questions

Apricus Biosciences, Inc. (NASDAQ:APRI) announced its earnings results on Wednesday, October, 31st. The company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.02.

Based on aggregate information from My MarketBeat watchlists, some other companies that Apricus Biosciences investors own include Scotts Miracle-Gro (SMG), Pfizer (PFE), Just Eat Takeaway.com (GRUB), Boston Beer (SAM), Amicus Therapeutics (FOLD), Palatin Technologies (PTN) and Synergy Pharmaceuticals (SGYP).

Company Calendar

Last Earnings
10/31/2018
Today
5/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:APRI
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$320 thousand
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$5.76 million
Price / Cash Flow
N/A
Book Value
$0.29 per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$14,000.00
Optionable
Not Optionable
Beta
1.20
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

This page (NASDAQ:APRI) was last updated on 5/31/2025 by MarketBeat.com Staff
From Our Partners